Prognostic Stage III Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Prognostic Stage 3 Breast Cancer AJCC v8

DBCOND0109635 (Prognostic Stage III Breast Cancer AJCC v8)Not Yet Recruiting1 IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment